Stocks and Investing
Stocks and Investing
Thu, October 3, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Raghuram Selvaraju Reiterated (URGN) at Strong Buy and Held Target at $60 on, Oct 3rd, 2024
Raghuram Selvaraju of HC Wainwright & Co., Reiterated "UroGen Pharma Ltd." (URGN) at Strong Buy and Held Target at $60 on, Oct 3rd, 2024.
Raghuram has made no other calls on URGN in the last 4 months.
There are 3 other peers that have a rating on URGN. Out of the 3 peers that are also analyzing URGN, 0 agree with Raghuram's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Raghuram
- Kelsey Goodwin of "Guggenheim" Initiated at Strong Buy and Held Target at $40 on, Thursday, August 22nd, 2024
- Leland Gershell of "Oppenheimer" Maintained at Buy with Increased Target to $40 on, Friday, June 14th, 2024
- Matthew Kaplan of "Ladenburg Thalmann" Maintained at Strong Buy with Increased Target to $54 on, Friday, June 14th, 2024
Contributing Sources